# EU-1-14-960_public-assessment-report_20150130_20150130_duavive-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
23 October 2014
EMA/CHMP/383987/2014
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Duavive
International non-proprietary name: ESTROGENS CONJUGATED /
BAZEDOXI FENE
Procedure No. EMEA/H/C/002314/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
10
10
1.1. Submission of the dossier
11
1.2. Manufacturers
1.3. Steps taken for the assessment of the product
12
2. Scientific discussion
12
2.1. Introduction
12
2.2. Quality aspects
14
2.2.1. Introduction
14
2.2.2. Active Substance
15
2.2.3. Finished Medicinal Product.
21
2.2.4. Discussion on chemical, pharmaceutical and biological aspects.
24
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
24
2.2.6. Recommendations for future quality development
24
2.3. Non-clinical aspects
26
2.3.1. Introduction
26
2.3.2. Pharmacology
26
2.3.3. Pharmacokinetics
29
2.3.4. Toxicology
29
2.3.5. Ecotoxicity/environmental risk assessment
33
2.3.6. Discussion on non-clinical aspects
35
2.3.7. Conclusion on the non-clinical aspects
37
2.4. Clinical aspects
38
2.4.1. Introduction
38
2.4.2. Pharmacokinetics
44
2.4.3. Pharmacodynamics
48
2.4.4. Discussion on clinical pharmacology.
49
2.4.5. Conclusions on clinical pharmacology
51
2.5. Clinical efficacy
52
2.5.1. Dose response study.
53
2.5.2. Main studies
56
2.5.3. Discussion on clinical efficacy
100
2.5.4. Conclusions on the clinical efficacy
104
2.6. Clinical safety
106
2.6.1. Discussion on clinical safety
123
2.6.2. Conclusions on the clinical safety
126
2.7. Pharmacovigilance
127
2.8. Risk Management Plan
128
Assessment report
EMA/CHMP/383987/2014
Page 2/153
